WO2009044899A1 - 細胞の増殖を制御する核酸 - Google Patents

細胞の増殖を制御する核酸 Download PDF

Info

Publication number
WO2009044899A1
WO2009044899A1 PCT/JP2008/068109 JP2008068109W WO2009044899A1 WO 2009044899 A1 WO2009044899 A1 WO 2009044899A1 JP 2008068109 W JP2008068109 W JP 2008068109W WO 2009044899 A1 WO2009044899 A1 WO 2009044899A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
proliferation
nucleic acid
regulating
acid capable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/068109
Other languages
English (en)
French (fr)
Inventor
Haruo Nakano
Tatsuya Miyazawa
Yoji Yamada
Tetsuo Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Priority to JP2009536125A priority Critical patent/JPWO2009044899A1/ja
Priority to EP08835543A priority patent/EP2208499A4/en
Priority to US12/681,417 priority patent/US20100305188A1/en
Publication of WO2009044899A1 publication Critical patent/WO2009044899A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　細胞の増殖抑制剤または増殖促進剤、細胞の増殖異常に起因する疾患の診断薬または治療薬、アポトーシス誘導剤、マイクロＲＮＡなどの核酸の標的遺伝子の発現抑制剤または発現促進剤、細胞の増殖抑制方法または増殖促進方法に関する。
PCT/JP2008/068109 2007-10-03 2008-10-03 細胞の増殖を制御する核酸 Ceased WO2009044899A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2009536125A JPWO2009044899A1 (ja) 2007-10-03 2008-10-03 細胞の増殖を制御する核酸
EP08835543A EP2208499A4 (en) 2007-10-03 2008-10-03 NUCLEIC ACID FOR REGULATING CELL PROLIFERATION
US12/681,417 US20100305188A1 (en) 2007-10-03 2008-10-03 Nucleic acid capable of regulating the proliferation of cell

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007260393 2007-10-03
JP2007-260393 2007-10-03

Publications (1)

Publication Number Publication Date
WO2009044899A1 true WO2009044899A1 (ja) 2009-04-09

Family

ID=40526314

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/068109 Ceased WO2009044899A1 (ja) 2007-10-03 2008-10-03 細胞の増殖を制御する核酸

Country Status (4)

Country Link
US (1) US20100305188A1 (ja)
EP (1) EP2208499A4 (ja)
JP (1) JPWO2009044899A1 (ja)
WO (1) WO2009044899A1 (ja)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10304719A1 (de) 2003-02-06 2004-08-26 Ifa-Technologies Gmbh Automatische Auswuchteinrichtung in einer Antriebswelle und Verfahren zum Betreiben derselben
WO2011108930A1 (en) * 2010-03-04 2011-09-09 Interna Technologies Bv A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
WO2011111715A1 (ja) * 2010-03-09 2011-09-15 協和発酵キリン株式会社 細胞周期を制御する核酸
WO2012161124A1 (ja) * 2011-05-20 2012-11-29 国立大学法人愛媛大学 マイクロｒｎａ又はその発現系を含む組成物
JP2013091611A (ja) * 2011-10-25 2013-05-16 Gifu Univ 間葉系細胞の分化調節剤およびこれを用いた医薬、並びに間葉系細胞への分化調節作用を有する物質のスクリーニング方法
WO2014126233A1 (ja) * 2013-02-15 2014-08-21 国立大学法人東京医科歯科大学 マイクロｒｎａの測定方法、並びに、がん治療剤及びこれを含有するがん治療のための医薬組成物
US9441222B2 (en) 2011-01-11 2016-09-13 Interna Technologies B.V. MiRNA for treating diseases and conditions associated with neo-angiogenesis
US9682095B2 (en) 2010-07-06 2017-06-20 Interna Technologies B.V. MiRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
US20170211074A1 (en) * 2016-01-21 2017-07-27 University Of South Carolina miRNA-489 IN TREATMENT OF BREAST CANCER
JP2023548208A (ja) * 2020-11-04 2023-11-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌｄ、ｐｆ－ｉｌｄおよびｉｐｆ治療用ウイルスベクターおよび核酸

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2604703B1 (en) 2005-03-14 2017-02-01 The Board of Trustees of the Leland Stanford Junior University Methods for evaluating graft survival in a solid organ transplant recipient
USRE46843E1 (en) 2005-03-14 2018-05-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
CA2814598A1 (en) 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
EP2487258B1 (en) 2006-01-05 2014-10-01 The Ohio State University Research Foundation MicroRNA-based methods for the diagnosis of colon, pancreas and stomach cancer
ES2446362T3 (es) 2006-03-20 2014-03-07 The Ohio State University Research Foundation Huellas de microARN durante megacariocipoyesis humana
CA2668961A1 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of Michigan Spink1 as a prostate cancer marker and uses thereof
ES2376509T3 (es) * 2007-07-06 2012-03-14 The Regents Of The University Of Michigan Reordenamientos de genes mipol 1-etv1.
JP2010535473A (ja) 2007-08-03 2010-11-25 ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン ｎｃＲＮＡをコードする超保存領域
CN101424640B (zh) * 2007-11-02 2012-07-25 江苏命码生物科技有限公司 血清中微小核糖核酸的检测方法和用于检测的试剂盒、生物芯片及其制作和应用方法
WO2009108853A1 (en) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation MicroRNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF GASTRIC CANCER
EP2387618B1 (en) 2009-01-15 2014-05-21 The Board of Trustees of The Leland Stanford Junior University Biomarker panel for diagnosis and prediction of graft rejection
EP2228444A1 (en) * 2009-03-09 2010-09-15 Julius-Maximilians-Universität Würzburg microRNA for diagnostic and therapeutic purposes in cardiovascular diseases
CN102712953A (zh) * 2009-09-17 2012-10-03 密歇根大学董事会 前列腺癌中的复发性基因融合物
US8916533B2 (en) 2009-11-23 2014-12-23 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
US9290813B2 (en) 2009-12-02 2016-03-22 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for determining an allograft tolerant phenotype
WO2011119980A1 (en) 2010-03-25 2011-09-29 The Board Of Trustees Of The Leland Stanford Junior University Protein and gene biomarkers for rejection of organ transplants
RU2585491C2 (ru) 2010-06-04 2016-05-27 Борд Оф Риджентс, Зе Юниверсити Оф Техас Систем Регуляция метаболизма с помощью mir-378
JP5931897B2 (ja) 2010-11-12 2016-06-08 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションＴｈｅ Ｏｈｉｏ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ マイクロｒｎａ−２１、ミスマッチ修復および結腸直腸癌に関連する物質および方法
CA2817982C (en) 2010-11-15 2020-06-30 The Regents Of The University Of Michigan Controlled release mucoadhesive systems
KR101852440B1 (ko) 2010-11-19 2018-04-27 (주)아모레퍼시픽 듀옥스 2 ｍｉＲＮＡ를 포함하는 피부 세포 분화 조절용 조성물
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
WO2012125554A2 (en) * 2011-03-11 2012-09-20 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of cancer
WO2012167145A2 (en) * 2011-06-01 2012-12-06 University Of Southern California Genome-scale analysis of aberrant dna methylation in colorectal cancer
WO2012177639A2 (en) * 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
AU2012323924A1 (en) 2011-10-14 2014-05-29 The Ohio State University Methods and materials related to ovarian cancer
GB2535914B (en) * 2011-10-19 2016-10-26 Council Scient Ind Res Biomarkers useful for detection of types, grades and stages of human breast cancer
WO2013079701A2 (en) * 2011-11-30 2013-06-06 University Of Bremen Expression of mirnas in placental tissue
CA2859430A1 (en) 2011-12-13 2013-06-20 Ohio State Innovation Foundation Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
WO2013170146A1 (en) 2012-05-10 2013-11-14 Uab Research Foundation Methods and compositions for modulating mir-204 activity
EP3536789A1 (en) * 2012-06-06 2019-09-11 Boehringer Ingelheim International GmbH Cell engineering using rnas
AU2013359076A1 (en) * 2012-12-14 2015-07-02 Anthrogenesis Corporation Anoikis resistant placental stem cells and uses thereof
US20180142307A1 (en) * 2014-02-11 2018-05-24 California Institute Of Technology Recording and mapping lineage information and molecular events in individual cells
WO2017024019A1 (en) * 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
SE540173C2 (en) * 2016-04-20 2018-04-24 Hiloprobe Ab Marker genes for colorectal cancer classification, method for judging lymph node metastasis for prognosis of colorectal cancer and kit therefor
CN108531615B (zh) * 2018-04-24 2021-11-12 河南农业大学 一种鸡HS6ST3基因43bp indel多态性标记及其应用、检测引物、试剂盒
CN108721319B (zh) * 2018-05-28 2020-04-28 中南大学 抑制circ_CLASP2的试剂在制备鼻咽癌治疗制剂中的应用及制剂
EP3841115A4 (en) * 2018-08-20 2022-08-24 University of Georgia Research Foundation, Inc. COMPOSITIONS AND METHODS TO INCREASE STAINING OF WHITE FAT TISSUE
WO2020153478A1 (ja) * 2019-01-25 2020-07-30 国立研究開発法人産業技術総合研究所 人工マイクロｒｎａ前駆体およびそれを含む改良されたマイクロｒｎａ発現ベクター
WO2020172338A1 (en) * 2019-02-19 2020-08-27 Whitehead Institute For Biomedical Research Methods and agents for modulating mitochondrial nad levels
EP4110348A4 (en) * 2020-02-24 2024-04-03 The Trustees of Indiana University Therapeutic delivery of locked nucleic acid conjugated antisense mir-1
CN115572764B (zh) * 2022-03-30 2024-06-21 江苏鹍远生物技术有限公司 一组肿瘤检测标志物及其用途
CN115920053B (zh) * 2022-12-23 2024-09-20 河北医科大学第四医院 Crx在肺癌诊断、治疗中的应用
CN116516016A (zh) * 2023-04-11 2023-08-01 西北农林科技大学 一种与绵羊尾长相关的单核苷酸多态性标记及其应用
CN118717987B (zh) * 2024-06-17 2025-05-13 中山大学孙逸仙纪念医院 Ccdc25抑制剂在制备预防和/或治疗心肌梗死和/或心肌缺血再灌注药物中的应用
CN121313661B (zh) * 2025-12-08 2026-04-14 浙江省肿瘤医院 Tmem119基因或蛋白在抗胃癌药物开发中的应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016538A1 (en) 1995-10-31 1997-05-09 Dnavec Research Inc. (-)-strand rna virus vector having autonomously replicating activity
WO1997016539A1 (en) 1995-11-01 1997-05-09 Dnavec Research Inc. Recombinant sendai virus
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
US20070142313A1 (en) * 2005-12-15 2007-06-21 Board Of Regents, The University Of Texas System MicroRNA1 therapies
WO2007081680A2 (en) * 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
WO2007081720A2 (en) * 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2007147409A2 (en) * 2006-06-19 2007-12-27 Københavns Universitet Ribozyme mediated stabilization of polynucleotides
WO2008103755A1 (en) * 2007-02-20 2008-08-28 Mayo Foundation For Medical Education And Research Treating cancer with viral nucleic acid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295604B1 (en) * 2004-02-09 2015-04-08 Thomas Jefferson University Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features
EP2290071B1 (en) * 2004-05-28 2014-12-31 Asuragen, Inc. Methods and compositions involving microRNA
CA2857881A1 (en) * 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
EP2487258B1 (en) * 2006-01-05 2014-10-01 The Ohio State University Research Foundation MicroRNA-based methods for the diagnosis of colon, pancreas and stomach cancer
JP2011505143A (ja) * 2007-11-30 2011-02-24 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション マイクロｒｎａ発現プロファイリング及び肺癌における末梢血ターゲティング
WO2009100161A2 (en) * 2008-02-04 2009-08-13 Fred Hutchinson Cancer Research Center Epigenetic silencing of mir-342 in colorectal cancer

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016538A1 (en) 1995-10-31 1997-05-09 Dnavec Research Inc. (-)-strand rna virus vector having autonomously replicating activity
WO1997016539A1 (en) 1995-11-01 1997-05-09 Dnavec Research Inc. Recombinant sendai virus
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
US20070142313A1 (en) * 2005-12-15 2007-06-21 Board Of Regents, The University Of Texas System MicroRNA1 therapies
WO2007081680A2 (en) * 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
WO2007081720A2 (en) * 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2007147409A2 (en) * 2006-06-19 2007-12-27 Københavns Universitet Ribozyme mediated stabilization of polynucleotides
WO2008103755A1 (en) * 2007-02-20 2008-08-28 Mayo Foundation For Medical Education And Research Treating cancer with viral nucleic acid

Non-Patent Citations (104)

* Cited by examiner, † Cited by third party
Title
"Molecular Cloning,3rd edition", 2001, COLD SPRING HARBOR PRESS, COLD SPRING HARBOR, NY
ACC. CHEM. RES., vol. 32, 1999, pages 624
ADAMS B.D. ET AL.: "The Micro-Ribonucleic Acid (miRNA) miR-206 Targets the Human Estrogen Receptor- (ER) and Represses ER Messenger RNA and Protein Expression in Breast Cancer Cell Lines", MOL. ENDOCRINOL., vol. 5, 21 May 2007 (2007-05-21), pages 1132 - 1147, XP008133173 *
BIOCHEMISTRY, vol. 28, 1989, pages 9508 - 9514
BIOSCIENCE AND INDUSTRY, vol. 50, 1992, pages 322
BIOTECHNIQUES, vol. 11, 1991, pages 474 - 485
BIOTECHNOLOGY, vol. 9, 1992, pages 358
CANCER CELL, vol. 9, 2006, pages 435 - 443
CANCER RESEARCH, vol. 64, 2004, pages 3753 - 3756
CANCER RESEARCH, vol. 66, 2006, pages 11590 - 11593
CANCER RESEARCH, vol. 67, 2007, pages 1424 - 1429
CANCER RESEARCH, vol. 67, 2007, pages 7713 - 7722
CELL TECHNOLOGY, vol. 16, 1997, pages 1463
CELL, vol. 113, 2003, pages 673 - 676
CELL, vol. 120, 2005, pages 635 - 647
CELL, vol. 124, 2006, pages 1169 - 1181
CELL, vol. 27, 1981, pages 223 - 231
CHEMISTRY & BIOLOGY, vol. 6, 1999, pages R33
CIRCULATION RESEARCH, vol. 82, 1998, pages 1023
CIRCULATION, vol. 83, 1992, pages 2007 - 2011
CURRENT BIOLOGY, vol. 15, 2005, pages R458 - R460
CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 3, 1999, pages 274
EXPERIMENTAL NEPHROLOGY, vol. 5, 1997, pages 429
FEMS MICROBIOLOGY REVIEWS, vol. 23, 1999, pages 257
FRONTIERS IN BIOSCIENCE, vol. 4, 1999, pages D497
GENES & DEVELOPMENT, vol. 15, 2000, pages 188 - 200
GENES DEV., vol. 13, 1999, pages 3191
GENOME RES., vol. 6, 1996, pages 639
GENOMICS, vol. 16, 1993, pages 325 - 332
HUM. GENE THER., vol. 3, 1991, pages 147 - 154
HUM. GENE THER., vol. 3, 1992, pages 267 - 275
HUM. GENE THER., vol. 3, 1992, pages 399
J. AM. CHEM. SOC., vol. 122, 2000, pages 6900
J. AM. CHEM. SOC., vol. 123, 2001, pages 4653
J. BIOL. CHEM., vol. 264, 1989, pages 12126 - 12129
J. BIOL. CHEM., vol. 264, 1989, pages 16985 - 16987
J. BIOL. CHEM., vol. 266, 1991, pages 14338 - 14342
J. IMMUNOL. METH., vol. 160, 1993, pages 81 - 88
J. IMMUNOL. METH., vol. 65, 1983, pages 55 - 63
J. MOL. BIOL., vol. 215, 1990, pages 403
KAGAKU, vol. 46, 1991, pages 681
METHODS IN ENZYMOLOGY, vol. 183, 1990, pages 63
METHODS IN ENZYMOLOGY, vol. 254, 1995, pages 419
MOLECULAR AND CELLULAR BIOLOGY, vol. 27, 2007, pages 2240 - 2252
MUTAT. RES., vol. 288, 1993, pages 103 - 112
NATURE GENET., vol. 8, 1994, pages 42
NATURE GENETICS, vol. 9, 1996, pages 103 - 104
NATURE METHOD, vol. 3, 2006, pages 27
NATURE REVIEWS CANCER, vol. 6, 2006, pages 259 - 269
NATURE REVIEWS GENETICS, vol. 5, 2004, pages 522 - 531
NATURE, vol. 294, 1981, pages 92 - 94
NATURE, vol. 295, 1982, pages 116 - 119
NATURE, vol. 432, 2004, pages 226
NATURE, vol. 432, 2004, pages 226 - 230
NATURE, vol. 435, 2005, pages 823 - 833
NATURE, vol. 435, 2005, pages 839 - 843
NATURE, vol. 447, 2007, pages 1130 - 1134
NIPPON RINSHO - JAPANESE JOURNAL OF CLINICAL MEDICINE, vol. 54, 1996, pages 2583
NIPPON RINSHO - JAPANESE JOURNAL OF CLINICAL MEDICINE, vol. 56, 1998, pages 563
NUCLEIC ACID RESEARCH, vol. 32, 2004, pages E188
NUCLEIC ACID RESEARCH, vol. 32, 2004, pages EL75
NUCLEIC ACID RESEARCH, vol. 33, 2005, pages E179
NUCLEIC ACIDS RESEARCH, vol. 26, 1998, pages 5237
NUCLEIC ACIDS RESEARCH, vol. 31, 2003, pages 3406 - 3415
NUCLEIC ACIDS RESEARCH, vol. 31, 2003, pages 3429 - 3431
NUCLEIC ACIDS RESEARCH, vol. 32, 2004, pages E43
NUCLEIC ACIDS RESEARCH, vol. 34, 2006, pages 1765 - 1771
ONCOGENES, vol. 26, 2007, pages 2799 - 2803
ONCOLOGY REPORTS, vol. 16, 2006, pages 845 - 850
PROC. NATL. ACAD. SCI. USA, vol. 101, 2004, pages 2999 - 3004
PROC. NATL. ACAD. SCI. USA, vol. 101, 2004, pages 9740 - 9744
PROC. NATL. ACAD. SCI. USA, vol. 102, 2005, pages 3627 - 3632
PROC. NATL. ACAD. SCI. USA, vol. 104, 2007, pages 15472 - 15477
PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 5399 - 5403
PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 7380 - 7384
PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7413 - 7417
PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 3410 - 3414
PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 4033 - 4037
PROC. NATL. ACAD. SCI. USA, vol. 87, 1991, pages 3655 - 3659
PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 4255 - 4259
PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 8850 - 8854
PROC. NATL. ACAD. SCI. USA, vol. 99, 2002, pages 15524 - 15529
RNA, vol. 13, 2007, pages 151 - 159
RNA, vol. 9, 2003, pages 277 - 279
RNAI METHOD AND ANTISENSE METHOD, KODANSHA, 2005
SAIBO KOGAKU, vol. 16, 1997, pages 1463 - 1473
SCIENCE, vol. 209, 1980, pages 1414 - 1422
SCIENCE, vol. 224, 1984, pages 994 - 996
SCIENCE, vol. 247, 1990, pages 1465 - 1468
SCIENCE, vol. 249, 1990, pages 1285 - 1288
SCIENCE, vol. 294, 2001, pages 853 - 858
SCIENCE, vol. 294, 2001, pages 858 - 862
SCIENCE, vol. 303, 2004, pages 83 - 86
See also references of EP2208499A4 *
SEMIN. ONCOL., vol. 11, 1984, pages 285 - 298
SHARMISTHA PAL ET AL.: "Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma", EMBO J., vol. 26, no. 15, 8 August 2007 (2007-08-08), pages 3558 - 3569, XP008133172 *
TOM STRACHAN AND ANDREW P. READ: "Human Genetics", 1996, BIOS SCIENTIFIC PUBLISHERS LIMITED
TRENDS GENET., vol. 7, 1991, pages 314
TRENDS GENET., vol. 7, 1991, pages 5
TRENDS IN BIOTECHNOLOGY, vol. 10, 1992, pages 132
TRENDS IN BIOTECHNOLOGY, vol. 10, 1992, pages 152
TRENDS IN BIOTECHNOLOGY, vol. 10, 1992, pages 87
TRENDS IN BIOTECHNOLOGY, vol. 16, 1998, pages 438
VIROLOGY, vol. 52, 1973, pages 456 - 467

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10304719B4 (de) 2003-02-06 2005-12-01 Ifa-Technologies Gmbh Auswuchteinrichtung für eine einen Hohlraum aufweisende hochzylindrische Kraftfahrzeugantriebswelle und Verfahren zum Betreiben derselben
DE10304719A1 (de) 2003-02-06 2004-08-26 Ifa-Technologies Gmbh Automatische Auswuchteinrichtung in einer Antriebswelle und Verfahren zum Betreiben derselben
WO2011108930A1 (en) * 2010-03-04 2011-09-09 Interna Technologies Bv A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
EP3214174A1 (en) * 2010-03-04 2017-09-06 InteRNA Technologies B.V. A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt
US9161947B2 (en) 2010-03-04 2015-10-20 Interna Technologies B.V. MiRNA molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with EMT
WO2011111715A1 (ja) * 2010-03-09 2011-09-15 協和発酵キリン株式会社 細胞周期を制御する核酸
US9682095B2 (en) 2010-07-06 2017-06-20 Interna Technologies B.V. MiRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
US9441222B2 (en) 2011-01-11 2016-09-13 Interna Technologies B.V. MiRNA for treating diseases and conditions associated with neo-angiogenesis
WO2012161124A1 (ja) * 2011-05-20 2012-11-29 国立大学法人愛媛大学 マイクロｒｎａ又はその発現系を含む組成物
JP6011945B2 (ja) * 2011-05-20 2016-10-25 公一 中城 マイクロｒｎａ又はその発現系を含む組成物
JP2013091611A (ja) * 2011-10-25 2013-05-16 Gifu Univ 間葉系細胞の分化調節剤およびこれを用いた医薬、並びに間葉系細胞への分化調節作用を有する物質のスクリーニング方法
JPWO2014126233A1 (ja) * 2013-02-15 2017-02-02 国立大学法人 東京医科歯科大学 マイクロｒｎａの測定方法、並びに、がん治療剤及びこれを含有するがん治療のための医薬組成物
WO2014126233A1 (ja) * 2013-02-15 2014-08-21 国立大学法人東京医科歯科大学 マイクロｒｎａの測定方法、並びに、がん治療剤及びこれを含有するがん治療のための医薬組成物
US9994843B2 (en) 2013-02-15 2018-06-12 National University Corporation Tokyo Medical And Dental University Method for assaying microRNA, cancer therapeutic agent, and medicinal composition containing same for cancer therapy
JP2018143248A (ja) * 2013-02-15 2018-09-20 国立大学法人 東京医科歯科大学 マイクロｒｎａの測定方法、並びに、がん治療剤及びこれを含有するがん治療のための医薬組成物
US10876115B2 (en) 2013-02-15 2020-12-29 National University Corporation Tokyo Medical And Dental University Method for assaying MicroRNA, cancer therapeutic agent, and medical composition containing same for cancer therapy
US20170211074A1 (en) * 2016-01-21 2017-07-27 University Of South Carolina miRNA-489 IN TREATMENT OF BREAST CANCER
US10053696B2 (en) * 2016-01-21 2018-08-21 University Of South Carolina MiRNA-489 in treatment of breast cancer
JP2023548208A (ja) * 2020-11-04 2023-11-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌｄ、ｐｆ－ｉｌｄおよびｉｐｆ治療用ウイルスベクターおよび核酸

Also Published As

Publication number Publication date
JPWO2009044899A1 (ja) 2011-02-17
EP2208499A4 (en) 2011-12-28
EP2208499A1 (en) 2010-07-21
US20100305188A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
WO2009044899A1 (ja) 細胞の増殖を制御する核酸
WO2008073919A3 (en) Mir-20 regulated genes and pathways as targets for therapeutic intervention
WO2008154333A3 (en) Mir-34 regulated genes and pathways as targets for therapeutic intervention
WO2009070805A3 (en) Mir-124 regulated genes and pathways as targets for therapeutic intervention
WO2009086156A3 (en) Mir-10 regulated genes and pathways as targets for therapeutic intervention
WO2008073920A3 (en) Mir-21 regulated genes and pathways as targets for therapeutic intervention
WO2008036741A3 (en) Mir-200 regulated genes and pathways as targets for therapeutic intervention
WO2011005860A3 (en) 5' phosphate mimics
WO2011133871A3 (en) 5'-end derivatives
WO2008085797A8 (en) miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
WO2009108856A3 (en) Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
WO2011123621A3 (en) 2' and 5' modified monomers and oligonucleotides
WO2008073922A3 (en) Functions and targets of let-7 micro rnas
WO2009108866A3 (en) Microrna signatures associated with cytogenetics and prognosis in acute myeloid leukemia (aml) and uses thereof
WO2009121152A8 (en) Gene signatures
WO2008082730A3 (en) Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
WO2009154835A3 (en) Compositions and methods related to mir-16 and therapy of prostate cancer
WO2008036776A3 (en) Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
AP2011005978A0 (en) 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation.
WO2009014650A3 (en) Recombinant vibrio cholerae exotoxins
WO2007139723A8 (en) Chemicallymodified oligonucleotide primers for nucleic acid amplification
WO2008073921A3 (en) Mir-126 regulated genes and pathways as targets for therapeutic intervention
WO2011043809A9 (en) Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
EP2374884A3 (en) Human miRNAs isolated from mesenchymal stem cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08835543

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009536125

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008835543

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12681417

Country of ref document: US